Co-Diagnostics updated its capital markets program by amending its at-the-market Equity Distribution Agreement with Maxim Group to remove the fixed aggregate dollar cap on sales, limiting future issuances only to shares currently registered under its effective shelf. Concurrently, the company extended its share-issuance and registration standstill with investors under its May 19, 2026 Securities Purchase Agreement through 5:00 pm Eastern Time on August 14, 2026. Together, these actions provide greater flexibility to access equity capital while honoring investor protections during the transition.
Agreement 1: Co-Diagnostics Amends ATM Deal With Maxim Group, Lifting Cap to Registered Shares
- Agreement type: Amendment to Equity Distribution Agreement for at-the-market offering
- Counterparty: Maxim Group
- Signed / Effective: Jul 27 2026 / same
- Duration / Termination: At will
- Reason: Increase flexibility for ATM share sales under registered capacity
Agreement 2: Co-Diagnostics Extends Share-Issuance Standstill With SPA Investors to Aug. 14, 2026
- Agreement type: Extension of issuance and registration standstill under Securities Purchase Agreement
- Counterparty: Investors under Securities Purchase Agreement
- Signed / Effective: Jul 27 2026 / same
- Duration / Termination: Until Aug 14 2026
- Reason: Maintain investor protections during financing adjustments
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.